JP2021527636A5 - - Google Patents

Info

Publication number
JP2021527636A5
JP2021527636A5 JP2020567510A JP2020567510A JP2021527636A5 JP 2021527636 A5 JP2021527636 A5 JP 2021527636A5 JP 2020567510 A JP2020567510 A JP 2020567510A JP 2020567510 A JP2020567510 A JP 2020567510A JP 2021527636 A5 JP2021527636 A5 JP 2021527636A5
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
membered
groups
compound according
Prior art date
Application number
JP2020567510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527636A (ja
JPWO2019236625A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035452 external-priority patent/WO2019236625A1/en
Publication of JP2021527636A publication Critical patent/JP2021527636A/ja
Publication of JP2021527636A5 publication Critical patent/JP2021527636A5/ja
Publication of JPWO2019236625A5 publication Critical patent/JPWO2019236625A5/ja
Priority to JP2024133796A priority Critical patent/JP7794910B2/ja
Pending legal-status Critical Current

Links

JP2020567510A 2018-06-04 2019-06-04 Ｅａａｔ２活性化因子およびその使用方法 Pending JP2021527636A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024133796A JP7794910B2 (ja) 2018-06-04 2024-08-09 Ｅａａｔ２活性化因子およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862680423P 2018-06-04 2018-06-04
US201862680418P 2018-06-04 2018-06-04
US62/680,423 2018-06-04
US62/680,418 2018-06-04
PCT/US2019/035452 WO2019236625A1 (en) 2018-06-04 2019-06-04 Eaat2 activators and methods of using thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024133796A Division JP7794910B2 (ja) 2018-06-04 2024-08-09 Ｅａａｔ２活性化因子およびその使用方法

Publications (3)

Publication Number Publication Date
JP2021527636A JP2021527636A (ja) 2021-10-14
JP2021527636A5 true JP2021527636A5 (https=) 2022-07-29
JPWO2019236625A5 JPWO2019236625A5 (https=) 2022-07-29

Family

ID=68771005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567510A Pending JP2021527636A (ja) 2018-06-04 2019-06-04 Ｅａａｔ２活性化因子およびその使用方法
JP2024133796A Active JP7794910B2 (ja) 2018-06-04 2024-08-09 Ｅａａｔ２活性化因子およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024133796A Active JP7794910B2 (ja) 2018-06-04 2024-08-09 Ｅａａｔ２活性化因子およびその使用方法

Country Status (9)

Country Link
US (3) US11702403B2 (https=)
EP (2) EP4685140A1 (https=)
JP (2) JP2021527636A (https=)
CN (1) CN112533601B (https=)
AU (1) AU2019282231B2 (https=)
CA (1) CA3102762A1 (https=)
ES (1) ES3041367T3 (https=)
IL (1) IL279199B1 (https=)
WO (1) WO2019236625A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3877376T3 (da) 2018-11-06 2023-10-02 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
CA3118908A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
AU2019374812B2 (en) 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
CN113939295B (zh) * 2019-03-20 2025-05-16 金翅雀生物公司 哒嗪酮及其使用方法
EP4149621B1 (en) * 2020-05-13 2024-10-30 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260756A (en) * 1979-11-15 1981-04-07 American Cyanamid Company 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines
US4404203A (en) * 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
AU691673B2 (en) * 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
CA2742411A1 (en) * 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
AUPR606401A0 (en) * 2001-07-02 2001-07-26 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
JP2003313169A (ja) * 2002-04-19 2003-11-06 Otsuka Chemical Holdings Co Ltd ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP4890439B2 (ja) * 2005-03-07 2012-03-07 杏林製薬株式会社 ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
AU2008219166B2 (en) * 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
US8426412B2 (en) 2008-04-08 2013-04-23 Dow Agrosciences, Llc. 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides
EP2196465A1 (en) * 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
US9447075B2 (en) * 2011-08-02 2016-09-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as EAAT2 activators
CN103664895B (zh) * 2012-08-28 2018-02-27 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及其用途
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
EP2953944B1 (en) * 2013-02-07 2017-04-26 Merck Patent GmbH Pyridazinone-amides derivatives
LT2953952T (lt) * 2013-02-07 2017-08-25 Merck Patent Gmbh Makrocikliniai piridazinono dariniai
KR102420322B1 (ko) * 2014-06-17 2022-07-13 키에시 파르마슈티시 엣스. 피. 에이. 포스포이노시타이드 3-키나아제 억제제로서 인돌리진 유도체
CN106467495A (zh) * 2015-08-19 2017-03-01 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及用途
WO2017123991A1 (en) 2016-01-15 2017-07-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators
WO2018081378A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr

Similar Documents

Publication Publication Date Title
JP2021527636A5 (https=)
JP2021105002A5 (https=)
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
JP2017511794A5 (https=)
CL2009000696A1 (es) Compuestos polisustituidos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento y la prevencion de enfermedades neurodegenerativas, de traumatismos cerebrales y epilepsia, enfermedades psiquiatricas, enfermedades inflamatorias, entre otras.
JP2014500235A5 (https=)
RU2014113548A (ru) Нейроактивные стероиды, композиции и их применения
TW200628475A (en) PI3-kinases
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
JP2003523996A5 (https=)
HRP20161559T1 (hr) Derivati imidazopiridazina kao modulatori receptora gabaa
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
RU2015112914A (ru) Бензимидазолы в качестве активных агентов для центральной нервной системы
RU2016131875A (ru) Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы
HRP20241558T1 (hr) Dvojni inhibitori magl i faah
JP2012515152A5 (https=)
EP4257190A3 (en) 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
RU2013105444A (ru) Конденсированные гетероциклические производные в качестве модуляторов s1p
KR20150120520A (ko) 소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물
JPWO2019236625A5 (https=)
BR112015027362A2 (pt) derivados de isoquinolina estimulantes de neurogênese
JP2012532858A5 (https=)
RU2015120651A (ru) Производные имидазопиридина
JP2017502069A5 (https=)
EP2772481A8 (en) Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof